Solutions · Genomics
Accelerated genome analysis that turns sequencing data into clinically useful results — from population screening to pharmacogenomic guidance for individual prescriptions.
Countries such as the United Kingdom, Estonia, Finland and Denmark have shown that national genomics programmes can improve diagnosis of rare diseases, guide cancer treatment and make prescribing safer. Moldova’s programme starts with population screening of about 1% of the population — approximately 24,000 genomes — with a clear path to expand to 5%, a fivefold increase in workload.
Read more: What national genomics programmes in Europe have achieved.
GPU‑accelerated pipelines process whole‑genome sequencing data from raw reads to variant calls in a fraction of the time required by traditional CPU‑based pipelines, making population‑scale screening practical.
A continuous service answers clinical pharmacogenomic requests: which medicines and doses are appropriate given a patient’s genetic profile. Results are designed to feed directly into treatment planning.
Variant databases are updated regularly. Our platform re‑analyses existing genomes when new evidence appears, so a result that was “uncertain” last year can become actionable today.
Models trained on aggregated, governed genomic data help researchers understand the genetic make‑up of the Moldovan population — knowledge that cannot be imported from elsewhere.
Genomic data is among the most sensitive personal data there is. All processing takes place on our on‑premise infrastructure in Moldova, with strict access control, audit trails and separation between identifiable clinical data and research datasets.
FAQ
Pharmacogenomics studies how a person’s genes affect their response to medicines. It helps clinicians choose drugs and doses that are more likely to work and less likely to cause adverse reactions.
Yes. Capacity is planned for expansion from 1% to 5% of the population, which is a fivefold increase in sequencing analysis load.
Only authorised clinicians and researchers, according to role‑based access rules and applicable law. Every access is logged.
Further reading
Four European countries have built national genomics programmes at scale, each with a different goal. Comparing what they sequenced, how they linked it to health records and how they returned results gives Moldova a practical blueprint for screening 1% of its population.
A 2023 Lancet trial showed that a 12-gene pharmacogenomic panel cut clinically relevant adverse drug reactions by about 30%. Here is what the evidence shows, how Estonia returns PGx results to its population, and what implementation takes.
Europe now has three layers of law governing health data and medical AI. Here is what GDPR, the European Health Data Space and the AI Act require, and what they mean for an EU candidate country building national healthcare AI.
Talk to our team about specification, supply, deployment and support — from a single hospital department to a national programme.